This BIOCOM Event offers a unique opportunity to gain insight into the strategies of pharma- and biotech companies.

This BIOCOM Event offers a unique opportunity to gain insight into the strategies of pharma- and biotech companies. Leading experts in the field will share their knowledge on how to successfully bring orphan drugs to the market.

Personalized Medicine – once seen as a threat to the Pharma Industry – is today viewed as a growth opportunity. In the future, the sale of pharmaceuticals must be redefined away from a bulk business as patients and treatments become individual and unique. Consequently, as the industry learns to deal with small populations, the development of orphan drugs becomes increasingly interesting.

In Europe, between 5,000 and 8,000 people suffer from a rare disease, most of them life-threatening or chronically debilitating. Orphan indications affect between 6% and 8% of the population in total. This is between 27 and 36 million people in the European Union who represent an interesting target group for the industry. However, the research, development, and marketing of orphan drugs must keep to strict guidelines.

Representatives from biotech and pharmaceutical companies, researchers, business developers, clinical trial- and marketing experts, as well as investors, advisers and patent lawyers cannot afford to miss this high-level event in the standout location of the Spanish Embassy in Berlin.

View PDF

More details

Find an actor

CMEF 201811.04.2018

China Medical Equipment Fair 2018 Shanghai - China April 11-14, 2018

Bilan - Les Métiers de Demain

Le magazine référence nous informe des nouvelles formations et de leur impact sur l'avenir des métiers de la santé...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn